CHARGED ALPHATMFrontier AI stock research

BDX · NYSE

Becton, Dickinson and Company

Medical Instruments & Supplies · United States

USD 186.173.0% daily changeQuote 2026-10-06 · USD
Market cap (USD)
US$50.71B
Trailing P/E
43.30x
Forward P/E
13.99x
Quarterly revenue growth
5.4%
Trailing net margin
4.2%
Indicated dividend yield
2.3%

Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-11-05 (provider estimate, not issuer-confirmed).

Company background

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Company website

Q3 FY2026

Go beyond the headline.

Becton Dickinson (BDX): The Miss That Wasn’t - And The Beat That Also Wasn’t

Published 2026-08-08

Comparable businesses

BDX peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

Market metrics · missing or inapplicable values shown as —
MetricBDXBecton, Dickinson and CompanySnapshot 2026-10-06Financial period: 2026-06-30MDLNMedline Inc.Snapshot 2026-10-06Financial period: 2026-06-27ALCAlcon Inc.Snapshot 2026-10-06Financial period: 2026-06-30Peer medianSimilar-size peers only
Market capMarket value, converted to USDUS$50.71BUS$49.42BUS$30.66BUS$40.04Bn=2
Forward P/EProvider forward earnings estimate13.99x23.29x15.98x19.64xn=2
EV / EBITDAEnterprise value / trailing EBITDA10.67x19.40x14.53x16.97xn=2
Revenue growthLatest quarter vs prior-year quarter5.4%11.6%8.7%10.2%n=2
Operating marginLatest reported quarter15.7%0.8%14.6%7.7%n=2
Free cash flow yieldTrailing cash flow / market cap8.8%1.7%4.2%2.9%n=2
Net debt / EBITDANet debt / trailing EBITDA2.63x3.95x1.60x2.77xn=2
Debt / equityTotal debt / positive book equity0.69x0.66x0.25x0.45xn=2
Trailing P/ETrailing twelve-month earnings43.30x91.83x48.05x69.94xn=2
Price / bookPrice / positive book equity per share2.08x2.78x1.42x2.10xn=2
EV / salesEnterprise value / trailing revenue2.90x1.63x3.22x2.42xn=2
Earnings growthLatest quarter vs prior-year quarter-31.4%262.0%——
Gross marginTrailing twelve months46.9%25.1%57.2%41.2%n=2
Net marginTrailing twelve months4.2%2.3%5.9%4.1%n=2
Return on equityProvider trailing return; positive equity only6.6%4.9%2.9%3.9%n=2
Free cash flow marginTrailing free cash flow / revenue19.9%2.8%11.7%7.3%n=2
Dividend yieldIndicated annual dividend / price2.3%—0.6%—
Earnings payoutProvider trailing dividend payout72.5%0.0%26.6%13.3%n=2
Current ratioCurrent assets / current liabilities0.86x4.33x2.09x3.21xn=2
BetaProvider historical market sensitivity0.28—0.73—

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for BDX

All available reporting periods
Q3 FY20262026-08-08
Q1 20262026-05-10

BDX Stock: EPS Beats, Revenue Misses — Q1 2026

Presentation · 2026-05-10 · YouTube

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.